Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
Proteon Therapeutics priced its IPO below its expected range, clearing $61 million to pay the way for its investigational vascular drug.
Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.
GlaxoSmithKline is considering taking its HIV joint venture public, tersely dropping hints of an IPO for ViiV Healthcare as it lays out plans to again slash R&D costs and refocus its business.
Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen would do better as two companies. And his firm, Third Point, has upped its stake in the Big Biotech, giving him a bigger stage from which to pressure executives.
Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.
As the promise of harnessing the immune system to fight cancer grabs headlines around the industry, venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics, a Cambridge, MA, startup with a hybrid approach to the field.
Following the FDA's advice, Omeros has hit the brakes on a mid-stage human trial of its Huntington's disease treatment in light of data from a separate animal study, news that tanked the biotech's share value.
Shire and AbbVie have formally called it quits on a planned $55 billion merger, leaving each company to get by on the merits of its own pipeline and talk up the benefits of life without the other.
Earlier this year, Cytokinetics tanked as its lead prospect, a treatment for amyotrophic lateral sclerosis (ALS), missed its primary endpoint and a slew of secondary goals in a mid-stage trial. But the drug did come through on one measure of lung function, and, upon analysis of the results, the biotech believes that could be its ticket to FDA approval.
A panel of FDA advisers voted unanimously in favor of approving Novartis' new anti-inflammatory treatment, an expected positive outcome for the company as it races to be first in line among what promises to be a crowded field.